United Therapeutics Corporation - Common Stock (UTHR)
498.51
-36.59 (-6.84%)
NASDAQ · Last Trade: Feb 26th, 12:24 PM EST
Detailed Quote
Previous Close
535.10
Open
530.01
Bid
497.41
Ask
499.61
Day's Range
496.44 - 532.25
52 Week Range
266.98 - 537.19
Volume
223,019
Market Cap
22.38B
PE Ratio (TTM)
17.87
EPS (TTM)
27.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
332,506
Chart
About United Therapeutics Corporation - Common Stock (UTHR)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation. Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need. Read More
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share was 14% above analysts’ consensus estimates.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United Therapeutics (NASDAQ:UTHR).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an external liver assist product, in patients with acute forms of liver failure, acute-on-chronic liver failure, and severe acute alcoholic hepatitis, collectively called acute liver failure (ALF).2
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
